You are invited to join BerGenBio’s management team and internationally distinguished Key Opinion Leader experts in AXL biology and therapeutic potential, for a Virtual R&D Day, which will take place on:
6 November 2020
13.00pm CET/04.00am PST/06.00am CST
The program for the event is outlined below. To register, please click here.
Preliminary Agenda (times in CET)
13:00 Introduction – Richard Godfrey, Chief Executive Officer, BerGenBio
Presentations from independent AXL experts, followed by Q&A sessions led by James Lorens, Chief Scientific Officer and Hani Gabra, Chief Medical Officer at BerGenBio
13:10 AXL in AML/MDS – Professor Sonja Loges, Director, Department of Personalised Oncology, University Hospital Mannheim and Division of Personalised Medical Oncology, German Cancer Research Center – DKFZ (Heidelberg, Germany)
13:40 AXL in lung cancer – Dr Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust (Manchester, UK)
14:10 AXL and viruses/COVID-19 – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)
14:40 AXL in fibrosis/IPF –Professor Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)
15:10 Bemcentinib clinical development plan – Hani Gabra, Chief Medical Officer, BerGenBio
15:25 Concluding remarks – Richard Godfrey, Chief Executive Officer, BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com